Trials / Completed
CompletedNCT03599713
A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)
A Phase 2 Study of INCMGA00012 in Participants With Metastatic Merkel Cell Carcinoma (POD1UM-201)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 107 (actual)
- Sponsor
- Incyte Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Retifanlimab | INCMGA00012 administered at 500 milligrams (mg) by intravenous infusion once every 4 weeks |
Timeline
- Start date
- 2019-02-25
- Primary completion
- 2022-01-21
- Completion
- 2024-06-28
- First posted
- 2018-07-26
- Last updated
- 2025-08-05
- Results posted
- 2023-05-03
Locations
65 sites across 12 countries: United States, Australia, Canada, Czechia, France, Germany, Hungary, Italy, Poland, Spain, Switzerland, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03599713. Inclusion in this directory is not an endorsement.